Proactive Investors - Run By Investors For Investors
Why invest in COSM?
Cosmos Holdiings Inc: THE INVESTMENT CASE

Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

Cosmos is a modern company, but the trade routes it relies on are ancient
Vial of pills
The way Cosmos operates in Europe is by arbitraging and profiting from price differences in brand-name drugs

It seems fitting that Cosmos Holdings Inc.(OTCMKTS:COSM), a Chicago-based pharmaceutical holding company, would have a subsidiary in Greece, which is one of the largest exporters in the European pharmaceutical parallel trade.

Cosmos is a modern company, but the trade routes it relies on are ancient, and in a way that the ancient Greeks might approve of it is building an empire in the pharma sector that extends from the Byzantine port city of Thessaloniki all the way through to Scandinavia.

The way Cosmos operates in the parallel trade market – which allows for the free movement of goods across Europe from lower value to higher value markets – is by arbitraging and profiting from price differences in brand-name drugs, which might cost less in Greece than they do in, say, Germany.

“We purchase as much in the way of excess-branded pharmaceuticals products as we can,” says Konstantinos Vassilopoulos, the U.S. finance manager of Cosmos, who is based in Chicago. “And we export those products to wholesalers throughout Europe.”

When considering Cosmos, one must glance first at its meteoric growth. When Cosmos began trading in the European parallel pharmaceutical market in the fourth quarter of 2015, it reported just US$533,000 in annual revenue and was only doing business in Germany, the UK, Greece and Poland. By last year, its yearly revenue figure was more than 56 times higher at US$30mln and the company was engaged in the wholesale pharma trade across Sweden, Jordan, the Netherlands, the United Arab Emirates and 12 other countries, and showing a gross profit of US$1.96mln.

Building a European-wide network

Cosmos’s first stop on its trading route is northern Europe. Keen to ramp up its presence in Germany, Cosmos’s management team is in discussions to acquire a German-based wholesaler that specializes in re-importing pharmaceuticals from other European Union countries. The motivation behind this proposed takeover is that Germany is the European country where drugs are most in demand since it is Europe’s largest economy and the country’s legislation favors the parallel importation of pharmaceutical products.

“Germany absorbs approximately 50% of the excess branded pharmaceuticals in the European pharmaceutical market. It’s the largest pharmaceutical parallel importer of products,” explains Vassilopoulos. “Quite a few synergies will come out of this German acquisition. We hope to have news concerning the acquisition within the next few months. We’re still in negotiations.”

Deal with Canadian marijuana company Marathon Global

The German acquisition is not Cosmos’s only recent advance in Europe. The group revealed just weeks ago that it would do a deal to distribute the Canadian cannabis supplier Marathon Global Inc.’s line of medical marijuana products across the EU.

The deal with the German wholesaler is still being ironed out and Europe’s medical marijuana market is still taking shape, but that is not much of a worry for Cosmos as it already boasts a wide network of clients looking to buy and sell pharmaceuticals across Europe.

The engine behind Cosmos Holdings

Indeed, Cosmos controls two businesses that are intertwined to support its growth. The first is Sky Pharm, a Thessaloniki-based company, which trades the excess amounts of as many as 500 medicines across Europe.

The second is Decahedron Ltd, a UK-based pharmaceutical wholesaler, which is also involved in the importing and exporting of drugs and medical devices across much of northern Europe as well as in the United Arab Emirates and Singapore.

Grigorios Siokas, Cosmos’s chief executive also owns Doc Pharma, a maker of food and vitamin supplements, which is headquartered in Thessaloniki. “Grigorios owns Doc Pharma and is leveraging its capabilities to help Cosmos enter into the Nutraceutical sector, he hopes to roll up his company into Cosmos when the time is right,” explains Vassilopoulos.

Push into dietary and natural food supplements

By selling Doc Pharma contract-manufactured dietary and natural food supplements, Cosmos is also taking steps to widen its repertoire beyond pharmaceuticals. With dietary supplements offering very attractive gross margins, management is bullish on rolling out of their own product line of supplements.

“Wholesale branded pharmaceutical products are the key revenue generators for the company,” says Vassilopoulos. “We will begin to add food supplements and other products to our distribution network in the coming quarters.”

Looking to the United States

Attention is now being focused on Europe, but the hope is that Cosmos’s reach will at some point extend to the U.S. This is why its management chooses to keep its headquarters in Chicago, despite Chief Executive Grigorios Siokas living in and conducting most of Cosmos’s business from Greece.

Going forward, the plan is for Cosmos’s management team to find acquisition targets that will enable it to get its wholesale business off to an explosive start in the US. The company will also look to sell its own nutritional supplements directly to US stores and expects to have a toe-hold in the US by early next year.

“We are keeping our eyes open for acquisitions in the US,” concludes Vassilopoulus. “We expect to enter the U.S. market in the near future.”

View full COSM profile View Profile

Cosmos Holdiings Inc Timeline

Related Articles

researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.